絞り込み

16732

広告

Early Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

著者 Osarogiagbon RU , Veronesi G , Fang W , Ekman S , Suda K , Aerts JG , Donington J
J Thorac Oncol.2019 Mar 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

2018 was a banner year for all thoracic oncology, but especially for early-stage non-small cell lung cancer (NSCLC). Three seminal events occurred in the approximately 18 months from mid-2017 to the end of 2018: in June 2017 at the American Society of Clinical Oncology Annual Meeting a small, relatively unheralded study from Max Diehn's group at Stanford University reported on the use of a novel 'cancer personalized profiling by deep sequencing' circulating tumor-DNA technology to identify minimal residual disease in patients after curative-intent radiation or surgery for NSCLC; in April 2018 at the American Association for Cancer Research Annual Meeting, Drew Pardoll presented a small pilot study of 21 patients who had received 2 doses of preoperative Nivolumab; in September 2018, at the 19 World Conference on Lung Cancer, Harry J. De Koning presented the long-awaited results of the Dutch-Belgian Lung Cancer Screening Trial (NELSON). These three seminal studies, along with others which are reviewed in this paper, promise to accelerate our progress towards a world in which lung cancer is identified early, more patients undergo curative-intent treatment that achieves the promised cure, and those at risk for failure after treatment are identified early, when the cancer remains most vulnerable. The day is round the corner when lung cancer is de-fanged and no longer the worldwide terror it currently is. We herein present an overview of the most recent body of work that moves us inexorably towards that day.
PMID: 30851441 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード